Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -121.46% | -215.64% | -135.85% | 345.29% | 464.57% |
| Total Depreciation and Amortization | 39.81% | 54.24% | 47.39% | 31.98% | 14.08% |
| Total Amortization of Deferred Charges | -- | 200.00% | 0.00% | -66.67% | -- |
| Total Other Non-Cash Items | 291.25% | 397.72% | 240.24% | -4,364.77% | -3,017.37% |
| Change in Net Operating Assets | -27.51% | 67.82% | 0.24% | -74.41% | -491.06% |
| Cash from Operations | 330.46% | 338.26% | 891.32% | 120.77% | -196.90% |
| Capital Expenditure | -100.72% | -35.27% | -213.00% | 71.85% | 85.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -196.42% | -117.50% | -357.31% | 56.17% | 85.89% |
| Total Debt Issued | -- | -100.00% | -100.00% | -100.00% | -72.30% |
| Total Debt Repaid | -27.86% | 91.39% | 92.64% | 93.74% | 94.81% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -124.73% | 87.56% | 89.39% | 87.29% | 96.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 699.59% | 120.70% | 109.33% | 93.95% | -1.41% |